• Single-ascending dose portion of study successfully completed 2.5 and 7 mg/kg levels
• Dose dependent immunosuppressive effect observed with continued favorable safety profile
• Substantial reduction in T cell activity highlights potential efficacy in autoimmune diseases

Immutep Limited, a late-stage immunotherapy company, has announced positive updates from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The single-ascending dose escalation portion of the trial has successfully completed the 2.5 and 7 mg/kg dosing levels of IMP761 with continued positive safety and efficacy data. IMP761 was well-tolerated with no treatment-related adverse reactions beyond mild intensity. Additionally, evidence of dose-dependent immunosuppressive effects with IMP761 was observed, with significant, long-lasting inhibition of the three T-cell-mediated intradermal reactions to a strong foreign antigen at day 2, 9, and 23. The substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases. Given the encouraging efficacy and safety to date, the trial will continue as planned, and additional updates are anticipated in the first half of 2026, including a potential presentation of data at a major medical conference.

The trial will continue as planned, and additional updates are anticipated in the first half of 2026, including a potential presentation of data at a major medical conference.